4.5 Review

Overview of the development and current use of CRM197 conjugate vaccines for pediatric use

Journal

VACCINE
Volume 28, Issue 27, Pages 4335-4339

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.04.072

Keywords

Conjugate vaccines; CRM197; Pediatric vaccines

Funding

  1. Novartis Vaccines

Ask authors/readers for more resources

Glycoconjugate vaccines have been proven safe and effective against various diseases in children. Although these vaccines have a history of effectiveness, there are still many unanswered questions to be addressed, including conjugate interference when multiple vaccines are administered at one time, expansion of serotype coverage, effectiveness in special populations, and issues relating to conjugate vaccine use in the developing world. This paper focuses on the use of CRM197 as a carrier protein, contrasting it to other carrier proteins used in single-antigen pediatric vaccines as well as identifying areas for future study. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available